We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Divests Unit to Chubb to Streamline Business
Read MoreHide Full Article
Cigna Corp. (CI - Free Report) will be divesting its life, accident and supplemental benefits businesses to insurer Chubb Limited (CB).
Per the deal, the company’s life, accident and supplemental benefits businesses in seven countries will be sold for $5.75 billion dollars. The transaction is expected to be completed in 2022.
This move is in sync with Cigna’s efforts to focus more on its global health services portfolio.
The deal will sell off Cigna's life, accident and supplemental benefits businesses in Hong Kong, Indonesia, Korea, New Zealand, Taiwan and Thailand as well its interest in a joint venture in Turkey. Cigna will, however, continue to operate its robust international health businesses in the Middle East, Europe, Hong Kong, Singapore and its joint ventures in Australia, China and India.
Proceeds from the deal will be used primarily for share repurchase. Cigna is steadily streamlining its business to focus on core growth areas. To this end, it divested its non-health insurance unit Group Life and Disability insurance business to New York Life, America’s largest mutual life insurer. Funds from this sale were used in paying off debt and share buybacks.
Time and again, Cigna has pursued acquisitions or partnered with healthcare systems for bolstering its partner networks and strengthening its U.S. presence. These initiatives provided a boost to the medical membership of the company. This year, the company’s medical customer growth is anticipated to be a minimum of 350,000 customers.
The healthcare provider has a strong cash balance and solid cash-generation abilities in place. These tailwinds enabled it to undertake several growth-related efforts and tactically deploy capital through share buybacks and dividend payments. Cigna has been a regular dividend paying company for a while now. Its dividend yield of 2% is higher than the industry’s figure of 1.2%. The company’s leverage ratio of 40.5% at the second-quarter end was almost in line with the company’s long-term debt-to-capitalization target of around 40%.
Some better-ranked stocks in the medical space are UnitedHealth Group Inc. (UNH - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) and Tenet Healthcare Corporation (THC - Free Report) , each presently carrying a Zacks Rank #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna (CI) Divests Unit to Chubb to Streamline Business
Cigna Corp. (CI - Free Report) will be divesting its life, accident and supplemental benefits businesses to insurer Chubb Limited (CB).
Per the deal, the company’s life, accident and supplemental benefits businesses in seven countries will be sold for $5.75 billion dollars. The transaction is expected to be completed in 2022.
This move is in sync with Cigna’s efforts to focus more on its global health services portfolio.
The deal will sell off Cigna's life, accident and supplemental benefits businesses in Hong Kong, Indonesia, Korea, New Zealand, Taiwan and Thailand as well its interest in a joint venture in Turkey.
Cigna will, however, continue to operate its robust international health businesses in the Middle East, Europe, Hong Kong, Singapore and its joint ventures in Australia, China and India.
Proceeds from the deal will be used primarily for share repurchase.
Cigna is steadily streamlining its business to focus on core growth areas. To this end, it divested its non-health insurance unit Group Life and Disability insurance business to New York Life, America’s largest mutual life insurer. Funds from this sale were used in paying off debt and share buybacks.
Time and again, Cigna has pursued acquisitions or partnered with healthcare systems for bolstering its partner networks and strengthening its U.S. presence. These initiatives provided a boost to the medical membership of the company. This year, the company’s medical customer growth is anticipated to be a minimum of 350,000 customers.
The healthcare provider has a strong cash balance and solid cash-generation abilities in place. These tailwinds enabled it to undertake several growth-related efforts and tactically deploy capital through share buybacks and dividend payments. Cigna has been a regular dividend paying company for a while now. Its dividend yield of 2% is higher than the industry’s figure of 1.2%. The company’s leverage ratio of 40.5% at the second-quarter end was almost in line with the company’s long-term debt-to-capitalization target of around 40%.
Cigna carries a Zacks Rank #3 (Hold), currently. Year to date, the stock has slipped 1.4% against its industry's rise of 13.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Image Source: Zacks Investment Research
Some better-ranked stocks in the medical space are UnitedHealth Group Inc. (UNH - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) and Tenet Healthcare Corporation (THC - Free Report) , each presently carrying a Zacks Rank #2 (Buy).